Ambit is a biopharmaceutical company. It is oriented on the creation, development, and commercialization of drugs. Their preparations are intended for the treatment of oncological, autoimmune and inflammatory diseases. Ambit tries to release the drug known as quizartinib (AC220). It is a one-time, oral potent, selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3). Now, it is undergoing clinical trials in patients with relapsed/refractory acute myeloid leukemia (AML). It is also used in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT).